Meeting Archive:
Hepatitis A and B Vaccines: Recommendations and Impact



 

Meeting Description:
Join Noele P. Nelson, MD, PhD, MPH, Medical Epidemiologist, Division of Viral Hepatitis, Centers for Disease Control and Prevention for an update on the immunogenicity and safety of hepatitis A and B vaccines, current Advisory Committee on Immunization Practices (ACIP) recommendations, and the impact of vaccine implementation on the changing epidemiology of hepatitis A and B diseases.
 
At the conclusion of this activity, participants will be able to:
  • Explain and apply ACIP recommendations for the use of hepatitis A and B vaccines
  • Identify vaccine-preventable risks for hepatitis A and B
  • Describe the epidemiology of hepatitis A and B and immunization rates
This webinar is supported by an unrestricted educational grant from Merck & Co., Inc. NFID policies restrict funders from controlling program content.
Details
Date: Wed, Oct 18, 2017
Time: 12:00 PM EDT
Duration: 1 hour
Host(s): National Foundation for Infectious Diseases
 Presenter Information
Moderator: William Schaffner, MD
Speaker Photo

Medical Director, National Foundation for Infectious Diseases
Professor of Preventive Medicine and Infectious Diseases
Vanderbilt University School of Medicine
Nashville, TN

Noele P. Nelson, MD, PhD, MPH
Speaker Photo

Medical Officer
Division of Viral Hepatitis
Centers for Disease Control and Prevention (CDC)
Atlanta, GA

Continuing Medical Education (CME)
Speaker Photo

NFID is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NFID designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Continuing Nursing Education (CNE)
 
This continuing nursing education activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation (OBN-001-91). It has been approved for a maximum of 1.0 contact hour.